This is a working overview of clinical development, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-14. Anything still debated is marked as such rather than presented as settled.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (solid) | -20 °C or below | Freezer storage with desiccant |
| Solubility | Soluble in water and aqueous buffer | Careful dissolution needed at higher concentrations |
| Appearance | White to off-white lyophilised powder | Visual inspection for discolouration |
| Primary analytical method | Reversed-phase HPLC with UV detection | Paired with mass spectrometry for identity |
| Common synonyms | Triple-agonist peptide; GLP-1/GIP/glucagon agonist | Naming varies across the literature |
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
In most cases, urinary retention is managed with dose reduction or by switching to another type of antidepressant. In extreme cases, patients may require treatment with bethanechol, a drug that reverses this particular side effect. A common problem with TCAs is sedation (drowsiness, lack of physical and mental alertness), but protriptyline is considered the least sedating agent among this class of agents. Its side effects are especially noticeable early in therapy. In most people, early TCA side effects decrease or disappear entirely with time, but, until then, patients taking protriptyline should take care to assess which side effects occur in them and should not perform hazardous activities requiring mental acuity or coordination. Protriptyline may increase the possibility of having seizures.
There have been proposals for reactors that consume nuclear waste and transmute it to other, less-harmful or shorter-lived, nuclear waste. In particular, the integral fast reactor was a proposed nuclear reactor with a nuclear fuel cycle that produced no transuranic waste and, in fact, could consume transuranic waste. It proceeded as far as large-scale tests but was eventually canceled by the U.S. Government. Another approach, considered safer but requiring more development, is to dedicate subcritical reactors to the transmutation of the left-over transuranic elements. An isotope that is found in nuclear waste and that represents a concern in terms of proliferation is Pu-239. The large stock of plutonium is a result of its production inside uranium-fueled reactors and of the reprocessing of weapons-grade plutonium during the weapons program. An option for getting rid of this plutonium is to use it as a fuel in a traditional light-water reactors (LWR). Several fuel types with differing plutonium destruction efficiencies are under study. Transmutation was banned in the United States in April 1977 by U. S. President Carter due to the danger of plutonium proliferation, but President Reagan rescinded the ban in 1981. Due to economic losses and risks, the construction of reprocessing plants during this time did not resume. Due to high energy demand, work on the method has continued in the European Union (EU). This has resulted in a practical nuclear research reactor called Myrrha in which transmutation is possible.
== GLP-1 and GIP receptor dual agonists == Tirzepatide is a dual agonist, targeting the GLP-1 and GIP receptors and given as a once-weekly injection. The FDA approved it for type 2 diabetes in May 2022. In the SURPASS-2 clinical trial, tirzepatide was compared directly against semaglutide, a GLP-1 mono-agonist, in nearly 1,900 adults with type 2 diabetes. Tirzepatide outperformed semaglutide at all doses in both reducing blood sugar and weight loss. At the highest dose, 60% of patients on tirzepatide achieved good blood sugar control and at least 10% weight loss, compared to only 22% of patients that did so on semaglutide. Side effects were mostly mild gastrointestinal symptoms, similar to other drugs in the GLP-1 class.
These numbers may be low due to insufficient food intake data. The concentrations of nicotine in vegetables are difficult to measure accurately, since they are very low (parts per billion range). The biological function of nicotine in the tobacco plant is as an antiherbivore neurotoxin. Some species have evolved resistance to nicotine, such as Manduca sexta. In the tobacco plant, it is produced in the roots, then transported to the leaves. It has little effect on the plant itself. Grafting the top of a tomato plant to a tobacco root does not harm the tomato plant despite accumulating nicotine in the leaves. Conversely, grafting the top of a tobacco plant to a tomato root does not harm the tobacco plant, despite not receiving nicotine.
Sources: en.wikipedia.org
Soon after the Big Bang, roughly 14 Gya (14 billion years ago), the only chemical elements present in the universe were hydrogen, helium, and lithium, the three lightest atoms in the periodic table. These elements gradually condensed into vast clouds of gas, which collapsed under gravity into rotating protostellar disks. Gravitational accretion of material at the hot and dense centers of these disks formed the first stars by the fusion of hydrogen. Early stars were massive and short-lived, producing all the heavier elements by stellar nucleosynthesis. Such element formation proceeds to its most stable element Iron-56. Heavier elements were formed during supernovas at the end of a star's lifecycle. Carbon, currently the fourth most abundant element in the universe, was formed mainly in white dwarf stars. As these stars reached the end of their lifecycles, they ejected heavier elements, including carbon and oxygen, throughout the universe. These allowed for the formation of rocky planets. According to the nebular hypothesis, the Solar System began to form 4.6 Gya with the gravitational collapse of part of a giant molecular cloud. Most of the collapsing mass collected in the center, forming the Sun, while the rest flattened into a protoplanetary disk out of which the planets formed.
== Function == The ELN gene encodes a protein that is one of the two components of elastic fibers. The encoded protein is rich in hydrophobic amino acids such as glycine and proline, which form mobile hydrophobic regions bounded by crosslinks between lysine residues. Multiple transcript variants encoding different isoforms have been found for this gene. Elastin's soluble precursor is tropoelastin.
== External links == Media related to Propranolol at Wikimedia Commons "Propranolol (Infantile Hemangioma): MedlinePlus Drug Information". MedlinePlus. "Propranolol ( Code - C62073 )". EVS Explore. "Propranolol Hydrochloride ( Code - C29382 )". EVS Explore.
== Further reading == Carruthers JD, Fagien S, Joseph JH, Humphrey SD, Biesman BS, Gallagher CJ, et al. (January 2020). "DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2)". Plastic and Reconstructive Surgery. 145 (1): 45–58. doi:10.1097/PRS.0000000000006327. PMC 6940025. PMID 31609882. Solish N, Carruthers J, Kaufman J, Rubio RG, Gross TM, Gallagher CJ (December 2021). "Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A". Drugs. 81 (18): 2091–2101. doi:10.1007/s40265-021-01631-w. PMC 8648634. PMID 34787840.
== Standard structure == The amino acids in a standard π-helix are arranged in a right-handed helical structure. Each amino acid corresponds to an 87° turn in the helix (i.e., the helix has 4.1 residues per turn), and a translation of 1.15 Å (0.115 nm) along the helical axis. Most importantly, the N-H group of an amino acid forms a hydrogen bond with the C=O group of the amino acid five residues earlier; this repeated i + 5 → i hydrogen bonding defines a π-helix. Similar structures include the 310 helix (i + 3 → i hydrogen bonding) and the α-helix (i + 4 → i hydrogen bonding).
Sources: en.wikipedia.org
In this case the equation can be used if the flow speed of the gas is sufficiently below the speed of sound, such that the variation in density of the gas (due to this effect) along each streamline can be ignored. Adiabatic flow at less than Mach 0.3 is generally considered to be slow enough. It is possible to use the fundamental principles of physics to develop similar equations applicable to compressible fluids. There are numerous equations, each tailored for a particular application, but all are analogous to Bernoulli's equation and all rely on nothing more than the fundamental principles of physics such as Newton's laws of motion or the first law of thermodynamics.
=== Growth hormone deficiency === IGF1 levels can be analyzed and used by physicians as a screening test for growth hormone deficiency (GHD), acromegaly and gigantism. However, IGF1 has been shown to be a bad diagnostic screening test for growth hormone deficiency. The ratio of IGF1 and insulin-like growth factor-binding protein 3 has been shown to be a useful diagnostic test for GHD.
In the United States, the FDA relaxed rules on prescription drug marketing in 1997, allowing advertisements targeted directly to consumers. Lilly-ICOS hired the Grey Worldwide Agency in New York, part of the Grey Global Group, to run the Cialis advertising campaign. Marketing for Cialis has taken advantage of its greater duration compared to its competitors in advertisements for the drug; Stuart Elliot of The New York Times opined: "The continuous presence of females in Cialis ads is a subtle signal that the drug makes it easier for them to set the pace with males, in contrast to the primarily male-driven imagery for Levitra and Viagra." Iconic themes in Cialis ads include couples side by side in matching bathtubs and the slogan "When the moment is right, will you be ready?" Cialis ads were unique among the ED drugs in mentioning specifics of the drug. As a result, Cialis ads were also the first to describe the side effects in an advertisement, as the FDA requires advertisements with specifics to mention side effects. One of the first Cialis ads aired at the 2004 Super Bowl. Just weeks before the Super Bowl, the FDA required more possible side effects to be listed in the advertisement, including priapism. Although many parents objected to the Cialis ad being aired during the Super Bowl, Janet Jackson's halftime "wardrobe malfunction" overshadowed Cialis. In January 2006, the Cialis ads were tweaked, adding a doctor on screen to describe side effects and only running ads where more than 90 percent of the audience are adults, effectively ending Super Bowl ads.
== Gene == The ALDH2 gene is about 44 kbp in length and contains at least 13 exons which encode 517 amino acid residues. Except for the signal NH2-terminal peptide, which is absent in the mature enzyme, the amino acid sequence deduced from the exons coincided with the reported primary structure of human liver ALDH2. Several introns contain Alu repetitive sequences. A TATA-like sequence (TTATAAAA) and a CAAT-like sequence (GTCATCAT) are located 473 and 515 bp, respectively, upstream from the translation initiation codon.
The most fundamental political ideals of the sans-culottes were social equality, economic equality, and popular democracy. They supported the abolition of all the authority and privileges of the monarchy, nobility, and Roman Catholic clergy, the establishment of fixed wages, the implementation of price controls to ensure affordable food and other essentials, and vigilance against counter-revolutionaries.
Sources: en.wikipedia.org
Mass spectrometry provides the most direct confirmation of molecular mass. Reversed-phase chromatography adds a retention-time signature that supports identity when compared against a reference standard. No single method is sufficient on its own.
Cool, dry conditions with desiccant are standard for the solid form. Long-term storage is usually at freezer temperatures, with short-term handling at refrigerator temperature. Vials are allowed to equilibrate before opening to prevent condensation.
Lipid conjugation increases hydrophobicity, which shifts chromatographic retention and can broaden peaks. It also creates additional related species when acylation is incomplete or the chain is oxidised. Methods are therefore developed to separate acylated and non-acylated forms explicitly.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.